A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Arisa Kita1,2 , Sena Yamamoto3 , Yuki Saito1 * and Takako S. Chikenji 3 *
1 Department of Anatomy, Sapporo Medical University School of Medicine, Sapporo, Japan, 2 Department of Plastic and Reconstructive Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan,
3 Graduate School of Health Sciences, Hokkaido University, Sapporo, Japan
Cellular senescence is a biological mechanism that prevents abnormal cell proliferation during tissue repair, and it is often accompanied by the secretion of various factors, such as cytokines and chemokines, known as the senescenceassociated secretory phenotype (SASP). SASP-mediated cell-to-cell communication promotes tissue repair, regeneration, and development. However, senescent cells can accumulate abnormally at injury sites, leading to excessive inflammation, tissue dysfunction, and intractable wounds. The effects of cellular senescence on skin wound healing can be both beneficial and detrimental, depending on the condition. Here, we reviewed the functional differences in cellular senescence that emerge during wound healing, chronic inflammation, and skin aging. We also review the latest mechanisms of wound healing in the epidermis, dermis, and subcutaneous fat, with a focus on cellular senescence, chronic inflammation, and tissue regeneration. Finally, we discuss the potential clinical applications of promoting and inhibiting cellular senescence to maximize benefits and minimize detrimental effects.
KEYWORDS
cellular senescence, senescence-associated secretory phenotypes (SASP), woundhealing, aged-skin, diabetic skin
EDITED BY
Chengliang Deng, Affiliated Hospital of Zunyi Medical University, China
REVIEWED BY
Eleni Mavrogonatou, National Centre of Scientific Research Demokritos, Greece Mariaceleste Aragona, University of Copenhagen, Denmark
*CORRESPONDENCE Takako S. Chikenji, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 Yuki Saito, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
RECEIVED 25 November 2023
ACCEPTED 05 February 2024
PUBLISHED 19 February 2024
CITATION
Kita A, Yamamoto S, Saito Y and Chikenji TS (2024), Cellular senescence and wound healing in aged and diabetic skin. Front. Physiol. 15:1344116.
doi: 10.3389/fphys.2024.1344116
COPYRIGHT
© 2024 Kita, Yamamoto, Saito and Chikenji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Michael Gold MD FAAD1 | Yoon-Soo Cindy Bae MD FAAD2 | David J. Goldberg MD JD FAAD3,4 | Sumayah Jamal MD PhD5 | Amy B. Lewis MD6 | Shari Marchbein MD FAAD7 | Adriana Ros DO8 | Uma Santhanam PhD9 | Lisa DiNatale9,10 | Jaime Emmetsberger PhD9,10
田潇雨 卢娜
中国药科大学,中国·江苏 南京 210000
摘 要
衰老(Senecence)是细胞功能逐渐退化的一种状态,在这种状态下细胞几乎丧失复制能力,并且细胞周期抑制基因p16INK4a 的表达升高。细胞衰老贯穿生物个体的整个生命过程,在各种生理以及病理过程中发挥重要的作用。一方面,衰老的细胞能够促进胚胎发育,伤口愈合和宿主免疫反应以及抑制肿瘤发生发展等。另一方面,随着年龄增长而在体内积累的衰老细胞也会对机体带来有害的影响。这些不能增殖的细胞产生衰老相关分泌表型(Senescence-Associated Secretory PhenotypeSASP),促进衰老相关疾病(Aging-related Diseae)的发生发展,而清除衰老细胞能够减缓衰老相关疾病的症状。因此寻找能够特异性杀死衰老细胞的药物(Senolytics)成为了抗衰老领域的研究重点。
关键词细胞衰老;衰老相关分泌表型;衰老相关疾病;抗衰老;Senolytics
Advances in Research on Senescence in Health and Diseases
Xiaoyu Tian Na Lu
China Pharmaceutical University, Nanjing, Jiangsu, 210000, China
AbstractSenescence is a state in which the cell's functional characteristics are gradually deteriorating, in which the cell is at a sustained lowevel ofreplication and is accompanied by an increase in the expression of the cell cycle inhibitor pl6lNK4a The production of senescent cells occurs throughout life and plays key roles in various physiological and pathological proceses. These noneproliferating celsoccupy key cellular niches and produce senescence-associated secretory phenotype (SASP) which contributes to aging-related diseasesprogress. Therefore, the search for Senolytics has become the focus ofresearch in the field of anti-aging.
Keywordscellular senescence, SASP, aging-related disease, anti-senescence, senolytics
刘淼 叶俊儒(成都医学院第一附属医院,成都610000)【摘要】研究抗衰老是当今社会的热点课题。干细胞是具有自我更新能力和多向分化能力的细胞,间充质干细胞包含其中。研究常用的间充质干细胞有骨髓间充质干细胞和脂肪间充质干细胞,二者均在组织修复和抗衰老方面有广泛的应用,有很好的发展前景。本文综述了近年来脂肪间充质干细胞抗衰老作用的特点、机制及应用研究进展。
【关键词】干细胞;骨髓间充质干细胞;脂肪间充质干细胞;抗衰老;组织修复【中图分类号】R725【文献标识码】A【文章编号】1005-1457(2017)04-30-7
Advances in the Theoretical Research of Mesenchymal Stem Cells
Liu Miao Ye Junru
( The first affiliated hospital ofchengdu medical college ,chengdu 610000 , China)Research on aging is a hot topic in today's society, Mesenchymal stem cells is a kind of stem cells, hasAbstraettheability to self-renewal and multi-directional differentiation potential, Research between commonly used there arebone marrow mesenchymal stem cells and adipose mesenchymal stem cells, mesenchymal stem cells between both intissue repair and anti-aning has a wide range of applications, In this paper,the characteristics,mechanism and applica-tion of the anti-aging effect of adipose mesenchymal stem cells in recent years are reviewd.
【Key words】Stem Cells; Bone Marrow mesenchymal stem cells; Adipose Mesenchymal stem cells; Ant- Aging; Tissue repair
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。